Targeting Cathepsin L (CTSL), whose upregulation is associated with poor clinical outcomes of breast cancer patients, may offer another approach that could be of significant benefit in the treatment of metastatic cancer patients. This evidence concerns the gene CTSL and breast carcinoma.